Glaukos Corporation (NYSE: GKOS) Stock Competitors & Peer Comparison
See GKOS's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GKOS and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GKOS | $189.45 | +1.51% | 11.2B | -220.30 | -$0.86 | N/A |
| ABT | $111.27 | +0.32% | 192.6B | 21.36 | $5.21 | +2.23% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $341.09 | -1.76% | 130.8B | 25.47 | $13.39 | +1.02% |
| MDT | $90.58 | -0.20% | 116B | 16.38 | $5.53 | +3.14% |
| BSX | $51.69 | +0.53% | 76.9B | 16.68 | $3.10 | N/A |
| EW | $92.56 | -0.53% | 53.3B | 34.29 | $2.70 | N/A |
| DXCM | $91.48 | +0.75% | 34.5B | 39.26 | $2.33 | N/A |
| RMD | $226.74 | +0.33% | 32.9B | 21.06 | $10.77 | +1.05% |
| PHG | $27.38 | +2.16% | 26.8B | 15.64 | $1.75 | +3.62% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
GKOS vs ABT Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ABT has a market cap of 192.6B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ABT trades at $111.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ABT's P/E ratio is 21.36. In terms of profitability, GKOS's ROE is -0.27%, compared to ABT's ROE of +0.11%. Regarding short-term risk, GKOS is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
GKOS vs BSX-PA Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, GKOS's ROE is -0.27%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, GKOS is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
GKOS vs SYK Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, SYK has a market cap of 130.8B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while SYK trades at $341.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas SYK's P/E ratio is 25.47. In terms of profitability, GKOS's ROE is -0.27%, compared to SYK's ROE of +0.16%. Regarding short-term risk, GKOS is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check SYK's competition here
Medtronic plc (NYSE: MDT)
GKOS vs MDT Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, MDT has a market cap of 116B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while MDT trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas MDT's P/E ratio is 16.38. In terms of profitability, GKOS's ROE is -0.27%, compared to MDT's ROE of +0.10%. Regarding short-term risk, GKOS is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
GKOS vs BSX Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, BSX has a market cap of 76.9B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while BSX trades at $51.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas BSX's P/E ratio is 16.68. In terms of profitability, GKOS's ROE is -0.27%, compared to BSX's ROE of +0.15%. Regarding short-term risk, GKOS is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
GKOS vs EW Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, EW has a market cap of 53.3B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while EW trades at $92.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas EW's P/E ratio is 34.29. In terms of profitability, GKOS's ROE is -0.27%, compared to EW's ROE of +0.10%. Regarding short-term risk, GKOS is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
GKOS vs DXCM Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, DXCM has a market cap of 34.5B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while DXCM trades at $91.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas DXCM's P/E ratio is 39.26. In terms of profitability, GKOS's ROE is -0.27%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, GKOS is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
GKOS vs RMD Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, RMD has a market cap of 32.9B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while RMD trades at $226.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas RMD's P/E ratio is 21.06. In terms of profitability, GKOS's ROE is -0.27%, compared to RMD's ROE of +0.24%. Regarding short-term risk, GKOS is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
GKOS vs PHG Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, PHG has a market cap of 26.8B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while PHG trades at $27.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas PHG's P/E ratio is 15.64. In terms of profitability, GKOS's ROE is -0.27%, compared to PHG's ROE of +0.10%. Regarding short-term risk, GKOS is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
GKOS vs ZBH Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ZBH has a market cap of 19.3B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ZBH trades at $99.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ZBH's P/E ratio is 11.74. In terms of profitability, GKOS's ROE is -0.27%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, GKOS is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
GKOS vs ABMD Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ABMD's P/E ratio is 65.36. In terms of profitability, GKOS's ROE is -0.27%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, GKOS is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
GKOS vs PEN Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while PEN trades at $326.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas PEN's P/E ratio is 85.36. In terms of profitability, GKOS's ROE is -0.27%, compared to PEN's ROE of +0.11%. Regarding short-term risk, GKOS is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
GKOS vs SNN Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while SNN trades at $30.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas SNN's P/E ratio is 14.17. In terms of profitability, GKOS's ROE is -0.27%, compared to SNN's ROE of +0.12%. Regarding short-term risk, GKOS is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
GKOS vs ALGN Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ALGN has a market cap of 12.6B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ALGN trades at $176.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ALGN's P/E ratio is 16.06. In terms of profitability, GKOS's ROE is -0.27%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, GKOS is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check ALGN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
GKOS vs SWAV Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas SWAV's P/E ratio is 78.76. In terms of profitability, GKOS's ROE is -0.27%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, GKOS is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SWAV's competition here
Globus Medical, Inc. (NYSE: GMED)
GKOS vs GMED Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while GMED trades at $85.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas GMED's P/E ratio is 19.36. In terms of profitability, GKOS's ROE is -0.27%, compared to GMED's ROE of +0.12%. Regarding short-term risk, GKOS is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check GMED's competition here
Insulet Corp. (NASDAQ: PODD)
GKOS vs PODD Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while PODD trades at $146.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas PODD's P/E ratio is 24.95. In terms of profitability, GKOS's ROE is -0.27%, compared to PODD's ROE of +0.27%. Regarding short-term risk, GKOS is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
GKOS vs BIO Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, BIO has a market cap of 9.7B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while BIO trades at $361.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas BIO's P/E ratio is 38.93. In terms of profitability, GKOS's ROE is -0.27%, compared to BIO's ROE of +0.03%. Regarding short-term risk, GKOS is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
GKOS vs BIO-B Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while BIO-B trades at $348.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas BIO-B's P/E ratio is 103.33. In terms of profitability, GKOS's ROE is -0.27%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, GKOS is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
GKOS vs MASI Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas MASI's P/E ratio is 44.43. In terms of profitability, GKOS's ROE is -0.27%, compared to MASI's ROE of +0.09%. Regarding short-term risk, GKOS is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
GKOS vs BRKR Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, BRKR has a market cap of 8.8B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while BRKR trades at $57.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas BRKR's P/E ratio is 29.11. In terms of profitability, GKOS's ROE is -0.27%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, GKOS is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
GKOS vs NARI Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas NARI's P/E ratio is -59.24. In terms of profitability, GKOS's ROE is -0.27%, compared to NARI's ROE of -0.00%. Regarding short-term risk, GKOS is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
GKOS vs LIVN Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while LIVN trades at $82.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas LIVN's P/E ratio is 19.19. In terms of profitability, GKOS's ROE is -0.27%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, GKOS is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
GKOS vs ITGR Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ITGR trades at $125.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ITGR's P/E ratio is 19.69. In terms of profitability, GKOS's ROE is -0.27%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, GKOS is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ITGR's competition here
Haemonetics Corporation (NYSE: HAE)
GKOS vs HAE Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, HAE has a market cap of 4.1B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while HAE trades at $90.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas HAE's P/E ratio is 18.06. In terms of profitability, GKOS's ROE is -0.27%, compared to HAE's ROE of +0.11%. Regarding short-term risk, GKOS is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check HAE's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
GKOS vs IRTC Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while IRTC trades at $123.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas IRTC's P/E ratio is -192.44. In terms of profitability, GKOS's ROE is -0.27%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, GKOS is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
GKOS vs AXNX Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas AXNX's P/E ratio is -709.80. In terms of profitability, GKOS's ROE is -0.27%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, GKOS is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
GKOS vs TMDX Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while TMDX trades at $89.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas TMDX's P/E ratio is 45.50. In terms of profitability, GKOS's ROE is -0.27%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, GKOS is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
GKOS vs AXGN Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while AXGN trades at $48.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas AXGN's P/E ratio is 126.45. In terms of profitability, GKOS's ROE is -0.27%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, GKOS is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
GKOS vs UFPT Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while UFPT trades at $319.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas UFPT's P/E ratio is 32.67. In terms of profitability, GKOS's ROE is -0.27%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, GKOS is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
GKOS vs BFLY Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while BFLY trades at $8.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas BFLY's P/E ratio is -36.79. In terms of profitability, GKOS's ROE is -0.27%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, GKOS is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
GKOS vs ESTA Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ESTA trades at $75.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ESTA's P/E ratio is -59.99. In terms of profitability, GKOS's ROE is -0.27%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, GKOS is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
GKOS vs NUVA Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas NUVA's P/E ratio is 75.00. In terms of profitability, GKOS's ROE is -0.27%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, GKOS is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
GKOS vs NVCR Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while NVCR trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas NVCR's P/E ratio is -11.36. In terms of profitability, GKOS's ROE is -0.27%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, GKOS is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
GKOS vs INSP Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while INSP trades at $58.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas INSP's P/E ratio is 25.62. In terms of profitability, GKOS's ROE is -0.27%, compared to INSP's ROE of +0.18%. Regarding short-term risk, GKOS is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
GKOS vs TNDM Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while TNDM trades at $23.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas TNDM's P/E ratio is -21.03. In terms of profitability, GKOS's ROE is -0.27%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, GKOS is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check TNDM's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
GKOS vs ATEC Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ATEC trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ATEC's P/E ratio is -162.50. In terms of profitability, GKOS's ROE is -0.27%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, GKOS is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
GKOS vs CNMD Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while CNMD trades at $49.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas CNMD's P/E ratio is 10.94. In terms of profitability, GKOS's ROE is -0.27%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, GKOS is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check CNMD's competition here
Enovis Corporation (NYSE: ENOV)
GKOS vs ENOV Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ENOV trades at $25.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ENOV's P/E ratio is 7.36. In terms of profitability, GKOS's ROE is -0.27%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, GKOS is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check ENOV's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
GKOS vs IART Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while IART trades at $18.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas IART's P/E ratio is 7.73. In terms of profitability, GKOS's ROE is -0.27%, compared to IART's ROE of -0.01%. Regarding short-term risk, GKOS is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
GKOS vs AORT Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while AORT trades at $28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas AORT's P/E ratio is 47.38. In terms of profitability, GKOS's ROE is -0.27%, compared to AORT's ROE of -0.01%. Regarding short-term risk, GKOS is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
GKOS vs HSKA Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas HSKA's P/E ratio is -62.49. In terms of profitability, GKOS's ROE is -0.27%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, GKOS is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check HSKA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
GKOS vs PRCT Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while PRCT trades at $21.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas PRCT's P/E ratio is -11.31. In terms of profitability, GKOS's ROE is -0.27%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, GKOS is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
GKOS vs AVNS Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas AVNS's P/E ratio is 27.77. In terms of profitability, GKOS's ROE is -0.27%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, GKOS is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
GKOS vs LMRI Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while LMRI trades at $12.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas LMRI's P/E ratio is -22.82. In terms of profitability, GKOS's ROE is -0.27%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, GKOS is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
GKOS vs SILK Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas SILK's P/E ratio is -18.96. In terms of profitability, GKOS's ROE is -0.27%, compared to SILK's ROE of -0.35%. Regarding short-term risk, GKOS is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
GKOS vs IRMD Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while IRMD trades at $87.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas IRMD's P/E ratio is 43.80. In terms of profitability, GKOS's ROE is -0.27%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, GKOS is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
GKOS vs FNA Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas FNA's P/E ratio is -19.83. In terms of profitability, GKOS's ROE is -0.27%, compared to FNA's ROE of -0.35%. Regarding short-term risk, GKOS is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
GKOS vs BVS Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, BVS has a market cap of 941M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while BVS trades at $13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas BVS's P/E ratio is 18.28. In terms of profitability, GKOS's ROE is -0.27%, compared to BVS's ROE of +0.28%. Regarding short-term risk, GKOS is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
GKOS vs CBLL Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, CBLL has a market cap of 882.2M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while CBLL trades at $23.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas CBLL's P/E ratio is -14.26. In terms of profitability, GKOS's ROE is -0.27%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, GKOS is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check CBLL's competition here
InMode Ltd. (NASDAQ: INMD)
GKOS vs INMD Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, INMD has a market cap of 873.7M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while INMD trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas INMD's P/E ratio is 10.56. In terms of profitability, GKOS's ROE is -0.27%, compared to INMD's ROE of +0.12%. Regarding short-term risk, GKOS is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check INMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
GKOS vs AVR Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, AVR has a market cap of 868.3M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while AVR trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas AVR's P/E ratio is -4.00. In terms of profitability, GKOS's ROE is -0.27%, compared to AVR's ROE of -0.78%. Regarding short-term risk, GKOS is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
GKOS vs CSII Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas CSII's P/E ratio is -20.83. In terms of profitability, GKOS's ROE is -0.27%, compared to CSII's ROE of -0.14%. Regarding short-term risk, GKOS is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
GKOS vs SIBN Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, SIBN has a market cap of 840.4M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while SIBN trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas SIBN's P/E ratio is -55.74. In terms of profitability, GKOS's ROE is -0.27%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, GKOS is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check SIBN's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
GKOS vs BBNX Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, BBNX has a market cap of 813.4M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while BBNX trades at $18.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas BBNX's P/E ratio is -11.97. In terms of profitability, GKOS's ROE is -0.27%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, GKOS is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BBNX's competition here
Varex Imaging Corporation (NASDAQ: VREX)
GKOS vs VREX Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, VREX has a market cap of 778.9M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while VREX trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas VREX's P/E ratio is 19.47. In terms of profitability, GKOS's ROE is -0.27%, compared to VREX's ROE of +0.05%. Regarding short-term risk, GKOS is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
GKOS vs AHCO Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, AHCO has a market cap of 775.5M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while AHCO trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas AHCO's P/E ratio is 11.63. In terms of profitability, GKOS's ROE is -0.27%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, GKOS is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
GKOS vs SSII Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, SSII has a market cap of 766.5M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while SSII trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas SSII's P/E ratio is -74.70. In terms of profitability, GKOS's ROE is -0.27%, compared to SSII's ROE of -0.27%. Regarding short-term risk, GKOS is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check SSII's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
GKOS vs BWAY Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, BWAY has a market cap of 646M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while BWAY trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas BWAY's P/E ratio is 41.84. In terms of profitability, GKOS's ROE is -0.27%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, GKOS is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BWAY's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
GKOS vs KIDS Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, KIDS has a market cap of 642.4M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while KIDS trades at $25.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas KIDS's P/E ratio is -21.19. In terms of profitability, GKOS's ROE is -0.27%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, GKOS is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check KIDS's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
GKOS vs CTKB Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, CTKB has a market cap of 631.5M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while CTKB trades at $4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas CTKB's P/E ratio is -25.91. In terms of profitability, GKOS's ROE is -0.27%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, GKOS is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
GKOS vs SRDX Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas SRDX's P/E ratio is -34.66. In terms of profitability, GKOS's ROE is -0.27%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, GKOS is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SRDX's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
GKOS vs DCTH Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, DCTH has a market cap of 599.3M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while DCTH trades at $17.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas DCTH's P/E ratio is 1736.00. In terms of profitability, GKOS's ROE is -0.27%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, GKOS is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check DCTH's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
GKOS vs APEN Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas APEN's P/E ratio is -9.43. In terms of profitability, GKOS's ROE is -0.27%, compared to APEN's ROE of -0.85%. Regarding short-term risk, GKOS is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check APEN's competition here
Cerus Corporation (NASDAQ: CERS)
GKOS vs CERS Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, CERS has a market cap of 572.3M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while CERS trades at $2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas CERS's P/E ratio is -56.69. In terms of profitability, GKOS's ROE is -0.27%, compared to CERS's ROE of -0.10%. Regarding short-term risk, GKOS is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check CERS's competition here
ZimVie Inc. (NASDAQ: ZIMV)
GKOS vs ZIMV Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, GKOS's ROE is -0.27%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, GKOS is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
GKOS vs TCMD Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, TCMD has a market cap of 534.8M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while TCMD trades at $23.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas TCMD's P/E ratio is 26.94. In terms of profitability, GKOS's ROE is -0.27%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, GKOS is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
GKOS vs NPCE Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, NPCE has a market cap of 494.7M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while NPCE trades at $14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas NPCE's P/E ratio is -22.32. In terms of profitability, GKOS's ROE is -0.27%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, GKOS is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
GKOS vs CLPT Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, CLPT has a market cap of 462.4M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while CLPT trades at $15.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas CLPT's P/E ratio is -13.07. In terms of profitability, GKOS's ROE is -0.27%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, GKOS is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
GKOS vs SGHT Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, SGHT has a market cap of 452.7M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while SGHT trades at $8.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas SGHT's P/E ratio is -14.86. In terms of profitability, GKOS's ROE is -0.27%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, GKOS is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check SGHT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
GKOS vs OFIX Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, OFIX has a market cap of 411.5M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while OFIX trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas OFIX's P/E ratio is -13.30. In terms of profitability, GKOS's ROE is -0.27%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, GKOS is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check OFIX's competition here
Carlsmed, Inc. (NASDAQ: CARL)
GKOS vs CARL Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, CARL has a market cap of 380.3M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while CARL trades at $13.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas CARL's P/E ratio is -9.78. In terms of profitability, GKOS's ROE is -0.27%, compared to CARL's ROE of -0.38%. Regarding short-term risk, GKOS is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
GKOS vs PACB Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, PACB has a market cap of 357.2M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while PACB trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas PACB's P/E ratio is -2.80. In terms of profitability, GKOS's ROE is -0.27%, compared to PACB's ROE of -49.62%. Regarding short-term risk, GKOS is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check PACB's competition here
Picard Medical, Inc. (AMEX: PMI)
GKOS vs PMI Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, PMI has a market cap of 354.8M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while PMI trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas PMI's P/E ratio is -2.88. In terms of profitability, GKOS's ROE is -0.27%, compared to PMI's ROE of +4.99%. Regarding short-term risk, GKOS is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check PMI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
GKOS vs CATX Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, CATX has a market cap of 352.4M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while CATX trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas CATX's P/E ratio is -2.19. In terms of profitability, GKOS's ROE is -0.27%, compared to CATX's ROE of -0.42%. Regarding short-term risk, GKOS is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check CATX's competition here
Electromed, Inc. (AMEX: ELMD)
GKOS vs ELMD Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ELMD has a market cap of 351.1M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ELMD trades at $42.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ELMD's P/E ratio is 36.24. In terms of profitability, GKOS's ROE is -0.27%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, GKOS is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
GKOS vs TLSI Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, TLSI has a market cap of 346.7M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while TLSI trades at $5.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas TLSI's P/E ratio is -3.35. In terms of profitability, GKOS's ROE is -0.27%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, GKOS is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
GKOS vs CV Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, CV has a market cap of 339.3M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while CV trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas CV's P/E ratio is -2.72. In terms of profitability, GKOS's ROE is -0.27%, compared to CV's ROE of +1.27%. Regarding short-term risk, GKOS is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check CV's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
GKOS vs SENS Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, SENS has a market cap of 323.1M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while SENS trades at $7.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas SENS's P/E ratio is -3.86. In terms of profitability, GKOS's ROE is -0.27%, compared to SENS's ROE of -1.66%. Regarding short-term risk, GKOS is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check SENS's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
GKOS vs SMLR Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas SMLR's P/E ratio is 3.92. In terms of profitability, GKOS's ROE is -0.27%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, GKOS is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
GKOS vs TMCI Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, TMCI has a market cap of 292.6M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while TMCI trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas TMCI's P/E ratio is -4.80. In terms of profitability, GKOS's ROE is -0.27%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, GKOS is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check TMCI's competition here
RxSight, Inc. (NASDAQ: RXST)
GKOS vs RXST Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, RXST has a market cap of 290.2M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while RXST trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas RXST's P/E ratio is -7.54. In terms of profitability, GKOS's ROE is -0.27%, compared to RXST's ROE of -0.17%. Regarding short-term risk, GKOS is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check RXST's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
GKOS vs ANIK Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ANIK has a market cap of 283.3M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ANIK trades at $21.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ANIK's P/E ratio is 43.20. In terms of profitability, GKOS's ROE is -0.27%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, GKOS is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check ANIK's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
GKOS vs MGRM Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas MGRM's P/E ratio is -12.00. In terms of profitability, GKOS's ROE is -0.27%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, GKOS is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check MGRM's competition here
Profound Medical Corp. (NASDAQ: PROF)
GKOS vs PROF Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, PROF has a market cap of 242.4M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while PROF trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas PROF's P/E ratio is -5.38. In terms of profitability, GKOS's ROE is -0.27%, compared to PROF's ROE of -0.56%. Regarding short-term risk, GKOS is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check PROF's competition here
Nevro Corp. (NYSE: NVRO)
GKOS vs NVRO Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas NVRO's P/E ratio is -1.91. In terms of profitability, GKOS's ROE is -0.27%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, GKOS is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
GKOS vs STIM Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, STIM has a market cap of 210.9M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while STIM trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas STIM's P/E ratio is -5.61. In terms of profitability, GKOS's ROE is -0.27%, compared to STIM's ROE of -1.51%. Regarding short-term risk, GKOS is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check STIM's competition here
Avita Medical Inc. (NASDAQ: RCEL)
GKOS vs RCEL Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, RCEL has a market cap of 199M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while RCEL trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas RCEL's P/E ratio is -5.10. In terms of profitability, GKOS's ROE is -0.27%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, GKOS is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check RCEL's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
GKOS vs BSGM Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas BSGM's P/E ratio is -5.81. In terms of profitability, GKOS's ROE is -0.27%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, GKOS is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
GKOS vs LUCD Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, LUCD has a market cap of 184.1M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while LUCD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas LUCD's P/E ratio is -2.61. In terms of profitability, GKOS's ROE is -0.27%, compared to LUCD's ROE of -0.02%. Regarding short-term risk, GKOS is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
GKOS vs MDGS Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas MDGS's P/E ratio is -0.27. In terms of profitability, GKOS's ROE is -0.27%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, GKOS is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check MDGS's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
GKOS vs FOCL Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, FOCL has a market cap of 178M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while FOCL trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas FOCL's P/E ratio is -5.80. In terms of profitability, GKOS's ROE is -0.27%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, GKOS is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check FOCL's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
GKOS vs QIPT Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas QIPT's P/E ratio is -15.87. In terms of profitability, GKOS's ROE is -0.27%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, GKOS is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
GKOS vs INGN Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, INGN has a market cap of 157.3M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while INGN trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas INGN's P/E ratio is -6.38. In terms of profitability, GKOS's ROE is -0.27%, compared to INGN's ROE of -0.13%. Regarding short-term risk, GKOS is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
GKOS vs QTRX Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, QTRX has a market cap of 134.7M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while QTRX trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas QTRX's P/E ratio is -1.79. In terms of profitability, GKOS's ROE is -0.27%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, GKOS is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
GKOS vs OWLT Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, OWLT has a market cap of 114.5M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while OWLT trades at $6.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas OWLT's P/E ratio is -45.21. In terms of profitability, GKOS's ROE is -0.27%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, GKOS is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
GKOS vs ICAD Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas ICAD's P/E ratio is -20.37. In terms of profitability, GKOS's ROE is -0.27%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, GKOS is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for GKOS.Check ICAD's competition here
Solana Company (NASDAQ: HSDT)
GKOS vs HSDT Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, HSDT has a market cap of 105.1M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while HSDT trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas HSDT's P/E ratio is -0.02. In terms of profitability, GKOS's ROE is -0.27%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, GKOS is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check HSDT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
GKOS vs HJLI Comparison August 2026
Glaukos Corporation (NYSE: GKOS) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GKOS stands at 11.2B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, GKOS is priced at $189.45 on the NYSE, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GKOS currently has a P/E ratio of -220.30, whereas HJLI's P/E ratio is N/A. In terms of profitability, GKOS's ROE is -0.27%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, GKOS is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for GKOS.Check HJLI's competition here